Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Actions and Investigations - Shareholders who purchased Telix securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - On July 22, 2025, Telix received a subpoena from the U.S. Securities and Exchange Commission regarding disclosures related to its prostate cancer therapeutic candidates, leading to a 10.44% drop in the price of Telix's American Depositary Shares on July 23, 2025 [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements since 2013 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased KBR, Inc. securities between May 6, 2025, and June 19, 2025, of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][5]. Group 1: Class Action Details - Investors who bought KBR securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by November 18, 2025 [3]. - The lawsuit alleges that KBR made materially false and misleading statements regarding its partnership with the U.S. Department of Defense's Transportation Command, which affected investors when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action settlements [4].

Core Viewpoint - A class-action lawsuit has been filed against KBR, Inc. alleging misleading statements to investors prior to the cancellation of a significant military contract, which adversely affected the company's business outlook [1][3]. Group 1: Lawsuit Details - The lawsuit seeks to represent investors who acquired KBR securities between May 6, 2025, and June 19, 2025 [1][2]. - The legal action claims that KBR executives provided an overly optimistic outlook on a crucial partnership just before its collapse [2]. Group 2: Contract Cancellation Impact - The lawsuit is linked to the Department of Defense's cancellation of a global household goods contract with HomeSafe Alliance LLC, a joint venture led by KBR, which was announced on June 20, 2025 [3]. - Following the contract termination, KBR shares dropped over 7% due to the loss of a contract valued at up to $20 billion over a potential nine-year term [3]. Group 3: Misrepresentation Allegations - On May 6, 2025, during its Q1 earnings call, KBR assured investors that the HomeSafe partnership was "strong" and projected a revenue contribution of about $400 million for 2025 [4]. - Just weeks later, on June 19, 2025, HomeSafe disclosed the termination of the contract due to operational issues, which KBR allegedly knew about but did not disclose to investors [5]. Group 4: Financial Guidance Revision - After the contract termination, KBR revised its low-end 2025 revenue guidance downward by approximately $900 million (-9%) on July 31, 2025, primarily due to the removal of the HomeSafe JV revenue contribution [6]. - KBR management acknowledged operational challenges during the earnings call following the revenue guidance revision [6].

Core Viewpoint - Rosen Law Firm is encouraging investors of Cepton, Inc. to secure legal counsel before the December 8, 2025 deadline for a class action lawsuit related to securities claims [1][3]. Group 1: Class Action Details - The class action pertains to investors who purchased or sold Cepton common stock between July 29, 2024, and January 6, 2025, and they may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 8, 2025 [3]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements [4]. Group 3: Allegations Against Cepton - The lawsuit alleges that Cepton's defendants made materially false and misleading statements regarding the company's business and operations, including failing to disclose a credible third-party bid that valued Cepton at more than double the Koito Acquisition [5]. - The Board of Directors is accused of not adequately exploring the third-party offer and failing to disclose its terms, depriving shareholders of the opportunity to make an informed decision regarding the Koito Acquisition [5].

Core Points - Rosen Law Firm is reminding investors of WPP plc to secure counsel before the December 8, 2025 lead plaintiff deadline for a securities class action related to American Depositary Shares purchased between February 27, 2025, and July 8, 2025 [1][2] Group 1: Class Action Details - Investors who purchased WPP ADSs during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by December 8, 2025 [3] - The complaint alleges that WPP provided misleading statements about its media arm's capabilities, leading to significant market share loss and investor damages when the truth was revealed [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors, including over $438 million in 2019 [4]

Core Viewpoint - Rosen Law Firm is reminding investors who bought or sold Cepton, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline on December 8, 2025 [1] Group 1: Class Action Details - Investors who purchased or sold Cepton common stock between July 29, 2024, and January 6, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 8, 2025 [3] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] Group 2: Case Allegations - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding Cepton's business and operations [5] - Specific allegations include that Cepton received a credible third-party bid valuing the company at more than double the Koito Acquisition, which was not disclosed to shareholders [5] - The Board of Directors allegedly failed to explore the third-party offer meaningfully and did not disclose its terms, depriving shareholders of the opportunity to consider the Koito Acquisition [5]

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of CarMax, Inc. (“CarMax” or the “Company”) (NYSE: KMX) between June 20, 2025 and September 24, 2025, inclusive. For more information, submit a form at CarMax, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 95 ...

Core Viewpoint - A class action securities lawsuit has been filed against RCI Hospitality Holdings, Inc. alleging securities fraud affecting investors between December 15, 2021, and September 16, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants engaged in tax fraud and bribery to conceal this fraud, leading to an understatement of the legal risks faced by the company [3]. - It is alleged that the defendants' statements regarding the company's business, operations, and prospects were materially false and misleading [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 20, 2025, to request to be appointed as lead plaintiff, although participation does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against ATyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [2][3]. Group 1: Legal Investigation - The firm is reminding investors of the December 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against ATyr Pharma [2]. - The complaint alleges that ATyr and its executives violated federal securities laws by making false statements and failing to disclose material adverse facts about Efzofitimod [3]. Group 2: Drug Efficacy and Market Impact - In the EFZO-FIT study, Efzofitimod did not show a significant change in mean daily oral corticosteroid dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [4]. - The study reported that complete steroid withdrawal was achieved in 52.6% of patients treated with Efzofitimod versus 40.2% on placebo [4]. - Following the release of these results, ATyr's stock plummeted by 83.25%, dropping from $6.03 on September 12 to $1.01 on September 15 [4].

Core Viewpoint - Rosen Law Firm is reminding purchasers of WPP plc American Depositary Shares (ADS) of the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during a specified period [1][5]. Group 1: Class Action Details - The class period for the lawsuit is from February 27, 2025, to July 8, 2025, and the lead plaintiff deadline is December 8, 2025 [1]. - Investors who purchased WPP ADSs during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. Group 3: Allegations Against WPP - The complaint alleges that WPP provided overly positive statements while concealing material adverse facts about its media arm, which was not adequately equipped to handle macroeconomic challenges and was losing market share [5].